Predictive Oncology Q2 loss $0.22/share; revenue $2.7K; ChemoFx U.S./EU launch expected Q4 2025

Axe Compute Inc.

Loss from continuing ops ~$2.0M; diluted EPS -$0.22 vs -$0.53 YoY.
Revenue $2,682, down 96% from $67,255 due to lower 3D model sales.
Cash $506K; stockholders' deficit $1.65M vs $202K at Dec 31, 2024.
Signed $10M standby equity purchase agreement with Yorkville Advisors.
Advanced ChemoFx market expansion; developed 3D liver models for Labcorp.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.